Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
13.52
+0.03 (0.22%)
At close: Jul 17, 2026, 4:00 PM EDT
13.50
-0.02 (-0.15%)
After-hours: Jul 17, 2026, 7:00 PM EDT
Organon & Co. Revenue
Organon & Co. had revenue of $1.46B in the quarter ending March 31, 2026, a decrease of -3.50%. This brings the company's revenue in the last twelve months to $6.16B, down -2.08% year-over-year. In the year 2025, Organon & Co. had annual revenue of $6.22B, down -2.92%.
Revenue (ttm)
$6.16B
Revenue Growth
-2.08%
P/S Ratio
0.58
Revenue / Employee
$616,300
Employees
10,000
Market Cap
3.55B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.22B | -187.00M | -2.92% |
| Dec 31, 2024 | 6.40B | 140.00M | 2.24% |
| Dec 31, 2023 | 6.26B | 89.00M | 1.44% |
| Dec 31, 2022 | 6.17B | -130.00M | -2.06% |
| Dec 31, 2021 | 6.30B | -228.00M | -3.49% |
| Dec 31, 2020 | 6.53B | -1.25B | -16.01% |
| Dec 31, 2019 | 7.78B | -2.00B | -20.46% |
| Dec 31, 2018 | 9.78B | -723.00M | -6.89% |
| Dec 31, 2017 | 10.50B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pfizer | 63.32B |
| Sanofi | 54.60B |
| Novo Nordisk | 50.57B |
| Bristol-Myers Squibb Company | 48.48B |
| GSK plc | 43.29B |
| Amgen | 37.22B |
| Gilead Sciences | 29.74B |
| Biogen | 9.94B |
OGN News
- 2 days ago - Organon & Co. Proxy statement: Proxy filing - Filings
- 3 days ago - Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing - Business Wire
- 26 days ago - Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA - Business Wire
- 27 days ago - Organon completes agreement to license MIUDELLA hormone-free IUD - TheFly
- 27 days ago - Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device - Business Wire
- 4 weeks ago - Organon and Samsung Bioepis expand commercialization agreement for Pyzchiva - TheFly
- 4 weeks ago - Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada - Business Wire
- 4 weeks ago - Organon & Co. Proxy statement: Proxy filing - Filings